Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Oculis to Present at Goldman Sachs Conference
Business conference participation

Oculis to Present at Goldman Sachs Conference

Analysis based on 6 articles · First reported Jun 08, 2026 · Last updated Jun 08, 2026

Sentiment
20
Attention
2
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The participation of Oculis in the Goldman Sachs Global Healthcare Conference provides a platform for the company to showcase its advanced pipeline, including Privosegtor and Licaminlimab. This exposure could lead to increased investor confidence and potentially a positive impact on Oculis's stock price as investors learn about its market opportunities and regulatory designations.

Biotechnology Pharmaceuticals
Event Summary

Oculis, a global biopharmaceutical company, announced its management's participation in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9, 2026, in Miami, FL. Dr. Riad Sherif, CEO of Oculis, will present an overview and update of the company's late-stage portfolio. Key highlights include Privosegtor, a neuroprotective candidate that received Breakthrough Therapy designation from the United States — Food and Drug Administration and Priority Medicines (PRIME) designation from the European Union — European Medicines Agency for optic neuritis, with a potential market opportunity of over $7 billion in the U.S. alone. Also featured is Licaminlimab, a topical anti-TNFa in a registrational trial for dry eye disease. Oculis aims to deliver several pivotal readouts with its current funding, focusing on its mission to improve eye care.

Key Actions
90 Oculis announced participation
80 Riad Sherif will present
70 United States — Food and Drug Administration granted designation Privosegtor
70 European Union — European Medicines Agency granted designation Privosegtor
Entities Involved
priv
Oculis
Oculis will present its late-stage portfolio and pipeline updates at the conference, potentially increasing investor interest and its stock value.
Importance 100 Sentiment 20
oth
Privosegtor
Privosegtor is a novel neuroprotective candidate by Oculis that received Breakthrough Therapy and PRIME designations, with a potential market opportunity of over $7 billion in the U.S. alone.
Importance 80 Sentiment 20
oth
Licaminlimab
Licaminlimab is a topical anti-TNFa being evaluated by Oculis in a registrational trial for dry eye disease, representing another key product candidate.
Importance 70 Sentiment 20
per
Riad Sherif
Dr. Riad Sherif, CEO of Oculis, will be the presenter at the fireside chat, representing the company.
Importance 60 Sentiment 0
stock
Goldman Sachs
Goldman Sachs is hosting the Global Healthcare Conference, providing a platform for Oculis to present its updates.
Importance 40 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration granted Breakthrough Therapy designation to Oculis's Privosegtor, highlighting its potential.
Importance 30 Sentiment 0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency granted Priority Medicines (PRIME) designation to Oculis's Privosegtor, indicating its importance.
Importance 30 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.